Lifesaving combined treatment in a rapidly progressive COVID-19 pneumonia case with extensive lung involvement
oleh: Seyed Mohammad Reza Hashemian, Razieh Farrokhi, Payam Tabarsi, Hamidreza Jamaati, Ali Akbar Velayati
| Format: | Article |
|---|---|
| Diterbitkan: | Wolters Kluwer Medknow Publications 2020-01-01 |
Deskripsi
COVID-19 pneumonia has rapid development into a global pandemic. For the infected patients, it is an urgent matter to improve the cure rate and reduce the death rate, but there are no effective antiviral drugs for COVID-19 so far. There is an urgent need for effective treatment. The current focus has been on the development of novel therapeutics, including antivirals and vaccines. One of these drugs, Favipiravir (Avigan), an antiviral agent approved for use in influenza in Japan, is being studied for the treatment of COVID-19. Herein, we report a patient; a 53 Y/O man without any underlying disease, developed COVID19 pneumonia rapidly and well respond to combination treatment including Dexamethasone, Favipiravir, and IFN-β-1a.